Literature DB >> 8058289

Factors contributing to the progression of visual field damage in eyes with normal-tension glaucoma.

M Araie1, M Sekine, Y Suzuki, N Koseki.   

Abstract

PURPOSE: To evaluate the contribution of various factors on the progression of visual field damage in normal-tension glaucoma.
METHODS: Follow-up data of 56 eyes of 56 patients with normal-tension glaucoma, all of whom had an early stage of the disease with a mean deviation of -5 decibels or greater and were followed without therapy, were analyzed using regression analysis of survival data based on the Cox proportional hazards model. Factors studied were age, sex, presence or absence of diabetes or family history of glaucoma, refraction, systolic and diastolic pressures, cup:disc ratio, ratio of area of parapapillary atrophy to disc area, the mean deviations of the studied and contralateral eyes, and intraocular pressure and occurrence of disc bleeding during follow-up, both of which were treated as time-dependent variables. The progression of visual field damage was based on the glaucoma change probability analysis.
RESULTS: Cup:disc ratio, ratio of area of parapapillary atrophy to disc area, and intraocular pressure were found to have significant influence on the progression of visual field damage in normal-tension glaucoma.
CONCLUSION: Intraocular pressure may be involved in the development of normal-tension glaucoma. However, further prospective studies are needed to determine the validity of such a conclusion.

Entities:  

Mesh:

Year:  1994        PMID: 8058289     DOI: 10.1016/s0161-6420(94)31153-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  33 in total

1.  Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 intraocular pressure control and complications.

Authors:  W L Membrey; D P Poinoosawmy; C Bunce; R A Hitchings
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Optical coherence tomography disc assessment in optic nerves with peripapillary atrophy.

Authors:  Edward Lai; Gadi Wollstein; Lori Lyn Price; Lelia A Paunescu; Paul C Stark; James G Fujimoto; Joel S Schuman
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2003 Nov-Dec

3.  Optic nerve head characteristics in eyes with papillomacular bundle defects in glaucoma.

Authors:  Aparna Rao; Sujoy Mukherjee; Debananda Padhy
Journal:  Int Ophthalmol       Date:  2015-02-27       Impact factor: 2.031

4.  Optic nerve compression by normal carotid artery in patients with normal tension glaucoma.

Authors:  N Ogata; M Imaizumi; H Kurokawa; M Arichi; M Matsumura
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

5.  Diurnal variation of intraocular pressure in suspected normal-tension glaucoma.

Authors:  Kou Hasegawa; Kyoko Ishida; Akira Sawada; Kazuhide Kawase; Tetsuya Yamamoto
Journal:  Jpn J Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 2.447

Review 6.  Normal tension glaucoma--a practical approach.

Authors:  D Kamal; R Hitchings
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

7.  Intraocular pressure and central visual field of normal tension glaucoma.

Authors:  M Araie; M Kitazawa; N Koseki
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

8.  Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 2 Visual field progression.

Authors:  W L Membrey; C Bunce; D P Poinoosawmy; F W Fitzke; R A Hitchings
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

9.  Characterization of peripapillary atrophy using spectral domain optical coherence tomography.

Authors:  Jung Hwa Na; Byung Gil Moon; Kyung Rim Sung; Youngrok Lee; Michael S Kook
Journal:  Korean J Ophthalmol       Date:  2010-11-23

10.  Intraocular pressure and visual field loss in primary angle closure and primary open angle glaucomas.

Authors:  G Gazzard; P J Foster; J G Devereux; F Oen; P Chew; P T Khaw; S Seah
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.